Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,416.00
Bid: 12,408.00
Ask: 12,410.00
Change: -12.00 (-0.10%)
Spread: 2.00 (0.016%)
Open: 12,474.00
High: 12,480.00
Low: 12,350.00
Prev. Close: 12,428.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MORNING BID-Asking for more stimulus?

Wed, 08th Jul 2020 09:04

* A look at the day ahead from EMEA deputy markets editor
Sujata
Rao. The views expressed are her own

LONDON, July 8 (Reuters) - Share markets are wavering after
snapping a five-day winning streak on Tuesday when world stocks
tumbled 1% and all three U.S. indexes closed in the red.

This morning, Wall Street futures and European equities are
both lower, Treasury yields are close to the one-week lows they
plumbed on Tuesday and German yields are 2 basis points lower.
China's Shanghai and Shenzhen benchmarks continued to march
higher in what's widely seen as a state-sanctioned rally.

In keeping with the jittery mood, the dollar is holding firm
as is gold. The Chinese rally has stoked demand for commodities,
pushing Shanghai copper to its highest in more than a year.
Chinese equity gains – the seventh day in a row – also pushed
emerging equities 0.7% higher.

The most obvious explanation for the pullback is the rise in
U.S. coronavirus cases, with 3 million confirmed cases and
localised activity restrictions. Atlanta Fed President Rafael
Bostic said there was a real sense the coronavirus crisis "might
go on longer than we have planned for".

Criticism of U.S President Donald Trump's handling of the
crisis is seen damaging his re-election chances, forcing Wall
Street to contend with the possibility of a Democrat
administration, higher taxes and tighter regulation.

Markets may also be hankering after another dose of stimulus
– Fed Vice Chair Richard Clarida said there was no limit to how
much bond buying the Fed could do.

The Cleveland Fed's Loretta Mester, meanwhile, called for
more help from the fiscal side. She may have hit the nail on the
head -- there's some unease as the scheme to supplement U.S.
jobless payments expires at the end of July just as the COVID-19
spike threatens to derail new hiring.

Consultancy Oxford Economics points out the worsening
coronavirus comes just as liquidity provision from central banks
and governments is slowing – central banks' balance-sheet growth
isn't accelerating any more, while some governments seem wary of
further fiscal measures that risk adding to debt.

Barclays said this morning in its annual equity-gilt study
that while all the extra borrowing is needed, deficits will need
to be addressed some day, with higher taxes part of the
solution.

Speaking of fiscal stimulus, British finance minister Rishi
Sunak is expected to announce measures to counter the jump in
unemployment. Aside from spending 3 billion pounds to improve
energy efficiency, he could announce VAT cuts, lower property
purchases taxes and vouchers to aid hospitality businesses. The
pound is holding near three-week highs before his speech.

In European corporate news, AstraZeneca and Merck &
Co said their cancer treatment Lynparza won European
Union approval for treating a form of pancreatic cancer.

Shares in Traton were down 3.6% after the company
announced management changes. Deutsche Post
was up 1.3% after reporting a 16% rise in
second-quarter operating profit.

In coronavirus-linked bad news, logistics company DHL may
cut as many as 2000 UK jobs, the Unite trade union said;
FirstGroup warned on its ability to continue as a going
concern, after posting an annual operating loss and plunging
passenger volumes; OMV second-quarter output dropped
5% in wake of coronavirus pandemic.

In emerging markets, China's yuan is near 7 to the dollar
after briefly breaking through the threshold on Tuesday.
Nigeria' naira fell 5.5% on Tuesday following central bank FX
sales at a lower rate -- possibly after pressure from lenders
and markets to unify its plethora of exchange rates.

Non-deliverable forwards see the naira losing a fifth of its
value over the next 12 months.
(Editing by Larry King
)

More News
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
13 Dec 2023 17:07

UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision

UK economy shrinks by 0.3% in October

*

Read more
12 Dec 2023 16:00

London close: Stocks slip as investors digest US inflation

(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.

Read more
12 Dec 2023 12:07

London midday: FTSE still firmer ahead of US inflation print

(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:53

LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI

(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.

Read more
12 Dec 2023 08:37

AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion

(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:16

AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn

(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.

Read more
12 Dec 2023 02:00

UK companies pause China investment decisions as economy slows, survey shows

BEIJING, Dec 12 (Reuters) - A slowdown in both the Chinese and global economies is the biggest issue affecting British firms in the world's second-largest economy, beating geopolitical concerns and market access barriers, according to the British Chamber of Commerce in China.

Read more
11 Dec 2023 08:15

AstraZeneca says danicopan tests well as blood disorder treatment

(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
1 Dec 2023 08:52

LONDON MARKET OPEN: Miners give FTSE 100 boost thanks to China PMI

(Alliance News) - Stock prices in London opened higher on Friday, with the FTSE 100 boosted by mining stocks.

Read more
1 Dec 2023 08:33

AstraZeneca discontinues two phase III evidence trials for Lokelma

(Alliance News) - AstraZeneca on Friday said it has decided to discontinue the Stabilize-CKD and Dialize-outcomes phase III trials for Lokelma, citing increased enrolment timelines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.